BofA raises Scholar Rock stock price target on FDA filing progress

BofA raised its price target on Scholar Rock to $58 from $51 (implying ~21% upside from the $48.07 share price) and maintained a Buy rating, while Truist ($55), BMO ($70) and Cantor Fitzgerald reaffirmed positive stances. Scholar Rock resubmitted its BLA for apitegromab following a positive FDA Type C meeting, adding two U.S. fill‑finish partners to address the sole CRL approvability issue (manufacturing) and expects a late‑September PDUFA date for the Class II refiling. BofA moved its U.S. launch estimate forward to Q4 2026 from mid‑2027, reducing perceived manufacturing/regulatory risk and supporting the upbeat analyst outlook.

Analysis

The practical market implication is a classic binary-biotech rerating: near-term regulatory optics (inspections, manufacturing qualification) will dominate realized returns over fundamental adoption dynamics for the next 3–6 months. Approval would likely compress time-to-revenue risk but not eliminate execution risk—fill-finish capacity constraints and CMC validation could create a 3–9 month lag between label event and meaningful net product sales, keeping stock moves volatile around supply milestones.

Roche’s program exit is a second-order structural benefit: it clears a head-to-head competitor path and concentrates commercial negotiation leverage with payors, but it simultaneously concentrates downside on any remaining single-supplier steps; payors and hospitals will push for clear redundancy in supply chains before granting preferred positioning, which could blunt pricing upside in Year 1. That dynamic raises the strategic value of having multiple validated manufacturing partners; it also increases acquirer interest but only conditional on demonstrable, auditable manufacturing reproducibility.

Regulatory execution remains the dominant tail risk — a follow-up inspection or a chemistry/controls finding could erase material value in days, while a clean inspection plus launch-readiness milestones could re-rate the equity by multiples within 6–18 months. For portfolio construction this argues for asymmetric option structures around the next regulatory cadence and for sizing equity exposure to reflect binary downside (40–60% post-adverse outcome) versus capped but meaningful upside (50–120% on approval and smooth supply).

Key Decisions for Investors

• Long SRRK equity (size 1–2% NAV) through the next 3–6 month regulatory window, trimming into any 40–60% pop; rationale: tail risk remains but upside is concentrated if manufacturing evidence is validated. Target hold 6–12 months, stop-loss 30%.
• Buy a 9–12 month SRRK call spread (buy 12-month ITM/near-ATM call, sell a higher strike call) to capture approval upside while capping premium; estimated IRR if approved ~2–4x on option spend, max loss = premium paid. Use this instead of naked calls to limit vega decay exposure.
• Hedge binary downside with protective puts: buy 3–6 month puts ~20–25% OTM sized 50% of equity position to cap rally-wiping inspection risk. Cost ~2–5% of NAV for modest protection depending on IV — preferred to shrinking equity size if conviction is medium.
• Event arbitrage — if an adverse manufacturing finding occurs, consider opening a short SRRK position sized 0.5–1% NAV with tight stops (target 30–50% downside capture within weeks). This is high-probability on inspection news but requires active risk controls.
• Monitor NVO (Novo) as a strategic-readout hedge: maintain a data alert on partner integration and fill-finish capacity announcements; if evidence shows capacity tightness, de-risk SRRK positions or widen protective hedges within 1–3 months.